Inhibrx Biosciences, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Inhibrx disclosed interim Phase 2 HexAgon trial data for INBRX-106 (hexavalent OX40 agonist) combined with pembrolizumab in first-line recurrent/metastatic head-and-neck squamous cell carcinoma (HNSCC). In HPV-positive patients (n=10 combo vs n=9 mono), combination achieved 80% confirmed objective response rate versus 33% for pembrolizumab alone, with 90% vs 33% progression-free survival at 6 months. The company plans to expand Phase 2 enrollment by 50 additional HPV+ patients, targeting potential accelerated approval by end of 2028/early 2029. INBRX-109 (ozekibart, DR5 agonist) achieved primary endpoint in chondrosarcoma with HR=0.479 (P=0.0001), more than doubling median PFS to 5.52 vs 2.66 months; anticipated approval and commercial launch in 2H 2027.
Why this rating
INBRX-106 data materially strengthens lead candidate; HPV+ signals support accelerated path and $4B+ market. Chondrosarcoma approval near. Company ~$175M market cap; meaningful catalysts ahead. However, early-stage Phase 2 data, small sample sizes, and regulatory path uncertain. Significant but not transformational yet.
Price action (we called it positive)
before filing · preread $101.71 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.